Literature DB >> 33085849

Assessing the Validity and Reliability of the Effects of Youngsters' Eyesight on Quality of Life Questionnaire Among Children With Uveitis.

Amy Cassedy1, Mekibib Altaye1, Jennifer Andringa1, Ashley M Cooper2, Carolyn Drews-Botsch3, George Engelhard4, Theresa Hennard1, Gary N Holland5, Kirsten Jenkins6, Scott R Lambert7, Jessi Lipscomb1, Courtney McCracken8, Deborah K McCurdy5, Joseph McDonald1, Najima Mwase1, Sampath Prahalad9, Erin Stahl2, Virginia Miraldi Utz1, A Adrienne Walker10, Steven Yeh8, Sheila T Angeles-Han1.   

Abstract

OBJECTIVE: The Effects of Youngsters' Eyesight on Quality of Life (EYE-Q) questionnaire measures vision-related functioning (VRF) and vision-related quality of life (VRQoL) in children with uveitis. Our aim was to revise the alpha version of the EYE-Q to refine VRF and VRQoL subscales and to assess the validity of the EYE-Q.
METHODS: Children with juvenile idiopathic arthritis (JIA), JIA-associated uveitis, and other noninfectious uveitis were enrolled. Patients and parents completed the EYE-Q, Pediatric Quality of Life Inventory (overall quality of life), and Childhood Health Assessment Questionnaire (physical functioning). The development site completed the alpha version of the EYE-Q, and the composite sites completed the beta version. We compared item-subscale correlations, internal consistency, and construct and discriminant validity among the different versions.
RESULTS: Of the 644 patients enrolled, 61.6% completed the alpha version, and 38.4% the beta version of the EYE-Q. Mean ± SD patient age was 11.1 ± 4.2 years, and 70% were female. Fewer White patients (73.5%) completed the alpha version compared to the beta version (86.2%; P < 0.001). With the exception of patient-reported VRF, both versions had similar item-subscale correlations. Version comparisons on scale internal consistencies indicated significant differences for parent- and patient-reported VRF, but each scale had a Cronbach's α of >0.80 beta. When data were combined, the EYE-Q showed significant differences between JIA-only and uveitis patients on all parent and patient scores, except for patient-reported VRF.
CONCLUSION: The EYE-Q appears to be a valid measure of VRF and VRQoL in pediatric uveitis. Our results suggest it may be used as an outcome measure in multicenter pediatric uveitis studies.
© 2020 American College of Rheumatology.

Entities:  

Mesh:

Year:  2022        PMID: 33085849     DOI: 10.1002/acr.24491

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  4 in total

Review 1.  Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.

Authors:  William D Renton; Jennifer Jung; Alan G Palestine
Journal:  Cochrane Database Syst Rev       Date:  2022-10-14

2.  Development of a Nationally Agreed Core Clinical Dataset for Childhood Onset Uveitis.

Authors:  Ameenat Lola Solebo; Salomey Kellett; Jugnoo Rahi; Reshma Pattani; Clive Edelsten; Andrew D Dick; Alastair Denniston
Journal:  Front Pediatr       Date:  2022-06-21       Impact factor: 3.569

3.  Ophthalmic sequelae and psychosocial impact in pediatric ebola survivors.

Authors:  Jessica G Shantha; Dominick Canady; Caleb Hartley; Amy Cassedy; Chris Miller; Sheila T Angeles-Han; Lloyd C M Harrison-Williams; Matthew J Vandy; Natalie Weil; Gilberte Bastien; Steven Yeh
Journal:  EClinicalMedicine       Date:  2022-06-03

4.  Comprehensive Assessment of Quality of Life, Functioning, and Mental Health in Children With Juvenile Idiopathic Arthritis and Noninfectious Uveitis.

Authors:  Joseph McDonald; Amy Cassedy; Mekibib Altaye; Jennifer Andringa; Ashley M Cooper; Carolyn Drews-Botsch; George Engelhard; Theresa Hennard; Gary N Holland; Kirsten Jenkins; Scott R Lambert; Jessi Lipscomb; Courtney McCracken; Deborah K McCurdy; Najima Mwase; Sampath Prahalad; Jessica Shantha; Erin Stahl; Virginia Miraldi Utz; A Adrienne Walker; Steven Yeh; Sheila T Angeles-Han
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-06-08       Impact factor: 5.178

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.